中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

宏基因组学测序技术在肝硬化脓毒症中的应用

贝小歌 陈金军 黎倍伶

贝小歌, 陈金军, 黎倍伶. 宏基因组学测序技术在肝硬化脓毒症中的应用[J]. 临床肝胆病杂志, 2021, 37(9): 2206-2209. DOI: 10.3969/j.issn.1001-5256.2021.09.041
引用本文: 贝小歌, 陈金军, 黎倍伶. 宏基因组学测序技术在肝硬化脓毒症中的应用[J]. 临床肝胆病杂志, 2021, 37(9): 2206-2209. DOI: 10.3969/j.issn.1001-5256.2021.09.041
BEI XG, CHEN JJ, LI BL. Application of metagenomic next-generation sequencing in sepsis in liver cirrhosis[J]. J Clin Hepatol, 2021, 37(9): 2206-2209. DOI: 10.3969/j.issn.1001-5256.2021.09.041
Citation: BEI XG, CHEN JJ, LI BL. Application of metagenomic next-generation sequencing in sepsis in liver cirrhosis[J]. J Clin Hepatol, 2021, 37(9): 2206-2209. DOI: 10.3969/j.issn.1001-5256.2021.09.041

宏基因组学测序技术在肝硬化脓毒症中的应用

DOI: 10.3969/j.issn.1001-5256.2021.09.041
基金项目: 

国家科技部重大专项 2018ZX10723203

国家科技部重大专项 2018ZX10302206

国家重点研发计划 2017YFC0908100

广东省珠江人才计划 2017BT01S131

南方医院"临床研究专项" 2018CR037

南方医院"临床研究专项" 2020CR026

南方医科大学临床启动计划 LC2019ZD006

详细信息
    通讯作者:

    陈金军,chjj@smu.edu.cn

    黎倍伶,lbling123@163.com

  • 中图分类号: R575.2

Application of metagenomic next-generation sequencing in sepsis in liver cirrhosis

Funds: 

National Science and Technology Major Project 2018ZX10723203

National Science and Technology Major Project 2018ZX10302206

National Key Research and Development Program of China 2017YFC0908100

Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program 2017BT01S131

Clinical Research Program of Nanfang Hospital 2018CR037

Clinical Research Program of Nanfang Hospital 2020CR026

Clinical Research Program of Nanfang Hospital, Southern Medical University LC2019ZD006

  • 摘要: 肝硬化患者由于持续的全身性炎症和免疫抑制状态,容易发生细菌感染,严重时可进展为脓毒症。早期有效的抗生素治疗是改善脓毒症患者预后的关键。简述了肝硬化患者发生脓毒症的病理生理机制及诊疗现状。认为宏基因组学测序技术可用于指导脓毒症的有效抗菌治疗。

     

  • [1] FERNÁNDEZ J, PRADO V, TREBICKA J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe[J]. J Hepatol, 2019, 70(3): 398-411. DOI: 10.1016/j.jhep.2018.10.027.
    [2] FERNÁNDEZ J, ACEVEDO J, CASTRO M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study[J]. Hepatology, 2012, 55(5): 1551-1561. DOI: 10.1002/hep.25532.
    [3] ARVANITI V, D'AMICO G, FEDE G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J]. Gastroenterology, 2010, 139(4): 1246-1256.e1-e5. DOI: 10.1053/j.gastro.2010.06.019.
    [4] QAZI SA, STOLL BJ. Neonatal sepsis: A major global public health challenge[J]. Pediatr Infect Dis J, 2009, 28(1 Suppl): s1-s2. DOI: 10.1097/INF.0b013e31819587a9.
    [5] ZHONG Y, XU F, WU J, et al. Application of next generation sequencing in laboratory medicine[J]. Ann Lab Med, 2021, 41(1): 25-43. DOI: 10.3343/alm.2021.41.1.25.
    [6] CAMPBELL KA, TRIVEDI HD, CHOPRA S. Infections in cirrhosis: A guide for the clinician[J]. Am J Med, 2021, 134(6): 727-734. DOI: 10.1016/j.amjmed.2021.01.015.
    [7] LEBOSSÉ F, GUDD C, TUNC E, et al. CD8+T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction[J]. EBio Medicine, 2019, 49: 258-268. DOI: 10.1016/j.ebiom.2019.10.011.
    [8] BERNSMEIER C, POP OT, SINGANAYAGAM A, et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK[J]. Gastroenterology, 2015, 148(3): 603-615.e14. DOI: 10.1053/j.gastro.2014.11.045.
    [9] BOUSSIF A, ROLAS L, WEISS E, et al. Impaired intracellular signaling, myeloperoxidase release and bactericidal activity of neutrophils from patients with alcoholic cirrhosis[J]. J Hepatol, 2016, 64(5): 1041-1048. DOI: 10.1016/j.jhep.2015.12.005.
    [10] LI BL, GAO YH, WANG XB, et al. Clinical features and outcomes of bacterascites in cirrhotic patients: A retrospective, multicentre study[J]. Liver Int, 2020, 40(6): 1447-1456. DOI: 10.1111/liv.14418.
    [11] ENGELMANN C, BECKER C, BOLDT A, et al. Ascites' neutrophil function is significantly impaired in patients with decompensated cirrhosis but can be restored by autologous plasma incubation[J]. Sci Rep, 2016, 6: 37926. DOI: 10.1038/srep37926.
    [12] NICOLETTI A, PONZIANI FR, BIOLATO M, et al. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation[J]. World J Gastroenterol, 2019, 25(33): 4814-4834. DOI: 10.3748/wjg.v25.i33.4814.
    [13] OKUMURA R, TAKEDA K. Maintenance of intestinal homeostasis by mucosal barriers[J]. Inflamm Regen, 2018, 38: 5. DOI: 10.1186/s41232-018-0063-z.
    [14] DI PASCOLI M, SACERDOTI D, PONTISSO P, et al. Molecular mechanisms leading to splanchnic vasodilation in liver cirrhosis[J]. J Vasc Res, 2017, 54(2): 92-99. DOI: 10.1159/000462974.
    [15] WANG L, FOUTS DE, STÄRKEL P, et al. Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation[J]. Cell Host Microbe, 2016, 19(2): 227-239. DOI: 10.1016/j.chom.2016.01.003.
    [16] GHOSH G, JESUDIAN AB. Small intestinal bacterial overgrowth in patients with cirrhosis[J]. J Clin Exp Hepatol, 2019, 9(2): 257-267. DOI: 10.1016/j.jceh.2018.08.006.
    [17] LAPIDOT Y, AMIR A, NOSENKO R, et al. Alterations in the gut microbiome in the progression of cirrhosis to hepatocellular carcinoma[J]. mSystems, 2020, 5(3). DOI: 10.1128/mSystems.00153-20.
    [18] DEL CAMPO JA, GALLEGO P, GRANDE L. Role of inflammatory response in liver diseases: Therapeutic strategies[J]. World J Hepatol, 2018, 10(1): 1-7. DOI: 10.4254/wjh.v10.i1.1.
    [19] ELCHANINOV AV, FATKHUDINOV TK, VISHNYAKOVA PA, et al. Phenotypical and functional polymorphism of liver resident macrophages[J]. Cells, 2019, 8(9): 1032. DOI: 10.3390/cells8091032.
    [20] CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740.
    [21] SINGER M, DEUTSCHMAN CS, SEYMOUR CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 801-810. DOI: 10.1001/jama.2016.0287.
    [22] VARON J, BARON RM. A current appraisal of evidence for the approach to sepsis and septic shock[J]. Ther Adv Infect Dis, 2019, 6: 2049936119856517. DOI: 10.1177/2049936119856517.
    [23] LIU ZC, YANG XS. Nutritional support treatment strategies for sepsis[J]. Chin J Dig Surg, 2019, 18(10): 920-923. DOI: 10.3760/cma.j.issn.1673-9752.2019.010.006.

    刘正才, 杨西胜. 脓毒症营养支持治疗策略[J]. 中华消化外科杂志, 2019, 18(10): 920-923. DOI: 10.3760/cma.j.issn.1673-9752.2019.010.006.
    [24] SEYMOUR CW, GESTEN F, PRESCOTT HC, et al. Time to treatment and mortality during mandated emergency care for sepsis[J]. N Engl J Med, 2017, 376(23): 2235-2244. DOI: 10.1056/NEJMoa1703058.
    [25] WHILES BB, DEIS AS, SIMPSON SQ. Increased time to initial antimicrobial administration is associated with progression to septic shock in severe sepsis patients[J]. Crit Care Med, 2017, 45(4): 623-629. DOI: 10.1097/CCM.0000000000002262.
    [26] RHODES A, EVANS LE, ALHAZZANI W, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016[J]. Crit Care Med, 2017, 45(3): 486-552. DOI: 10.1097/CCM.0000000000002255.
    [27] BARTOLETTI M, GIANNELLA M, LEWIS R, et al. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients[J]. Clin Microbiol Infect, 2018, 24(5): 546. e1-546. e8. DOI: 10.1016/j.cmi.2017.08.001.
    [28] PIANO S, SINGH V, CARACENI P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide[J]. Gastroenterology, 2019, 156(5): 1368-1380.e10. DOI: 10.1053/j.gastro.2018.12.005.
    [29] HARBARTH S, GARBINO J, PUGIN J, et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis[J]. Am J Med, 2003, 115(7): 529-535. DOI: 10.1016/j.amjmed.2003.07.005.
    [30] KUMAR A, ELLIS P, ARABI Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock[J]. Chest, 2009, 136(5): 1237-1248. DOI: 10.1378/chest.09-0087.
    [31] SINGER M. Antibiotics for sepsis: Does each hour really count, or is it incestuous amplification?[J]. Am J Respir Crit Care Med, 2017, 196(7): 800-802. DOI: 10.1164/rccm.201703-0621ED.
    [32] ZHONG Y, XU F, WU J, et al. Application of next generation sequencing in laboratory medicine[J]. Ann Lab Med, 2021, 41(1): 25-43. DOI: 10.3343/alm.2021.41.1.25.
    [33] LIPPI G. Sepsis biomarkers: Past, present and future[J]. Clin Chem Lab Med, 2019, 57(9): 1281-1283. DOI: 10.1515/cclm-2018-1347.
    [34] KIM H, HUR M, MOON HW, et al. Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis[J]. Ann Intensive Care, 2017, 7(1): 27. DOI: 10.1186/s13613-017-0252-y.
    [35] PALACIOS G, DRUCE J, DU L, et al. A new arenavirus in a cluster of fatal transplant-associated diseases[J]. N Engl J Med, 2008, 358(10): 991-998. DOI: 10.1056/NEJMoa073785.
    [36] XU B, LIU L, HUANG X, et al. Metagenomic analysis of fever, thrombocytopenia and leukopenia syndrome (FTLS) in Henan Province, China: Discovery of a new bunyavirus[J]. PLoS Pathog, 2011, 7(11): e1002369. DOI: 10.1371/journal.ppat.1002369.
    [37] LANGLEY RJ, WONG HR. Early diagnosis of sepsis: Is an integrated omics approach the way forward?[J]. Mol Diagn Ther, 2017, 21(5): 525-537. DOI: 10.1007/s40291-017-0282-z.
    [38] ROZO M, SCHULLY KL, PHILIPSON C, et al. An observational study of sepsis in takeo province cambodia: An in-depth examination of pathogens causing severe infections[J]. PLoS Negl Trop Dis, 2020, 14(8): e0008381. DOI: 10.1371/journal.pntd.0008381.
    [39] GRUMAZ S, GRUMAZ C, VAINSHTEIN Y, et al. Enhanced performance of next-generation sequencing diagnostics compared with standard of care microbiological diagnostics in patients suffering from septic shock[J]. Crit Care Med, 2019, 47(5): e394- e402. DOI: 10.1097/CCM.0000000000003658.
    [40] GRUMAZ S, STEVENS P, GRUMAZ C, et al. Next-generation sequencing diagnostics of bacteremia in septic patients[J]. Genome Med, 2016, 8(1): 73. DOI: 10.1186/s13073-016-0326-8.
    [41] GRENINGER AL. The challenge of diagnostic metagenomics[J]. Expert Rev Mol Diagn, 2018, 18(7): 605-615. DOI: 10.1080/14737159.2018.1487292.
  • 加载中
计量
  • 文章访问数:  44
  • HTML全文浏览量:  25
  • PDF下载量:  11
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-02-03
  • 修回日期:  2021-05-07
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回